mhurhangee/ep-ind-claims huggingface dataset:
A method of manufacturing an organic electronic device, comprising: - providing a layered device structure, the layered device structure comprising a plurality of electrodes (1, 5; 10, 14, 18) and an electronically active region being provided in electrical contact with at least one of the plurality of electrodes (1, 5; 10, 14, 18), said providing of the layered device structure comprising steps of - providing an organic semiconducting layer (3; 12, 16), - applying a structuring layer to the organic semiconducting layer (3; 12, 16), the structuring layer having a first region and a second region, the first region being covered by a layer material, - applying a contact improving layer (4; 13) at least in the first region by depositing an organic dopant material, - removing the structuring layer at least in the second region, and - structuring the contact improving layer, wherein removing the structuring layer comprises using a photo lithographic process, characterized in that the organic dopant material is soluble in Hydrofluorether, and the photo lithographic process is performed by using a fluorine based photo lithography. - providing a layered device structure, the layered device structure comprising a plurality of electrodes (1, 5; 10, 14, 18) and an electronically active region being provided in electrical contact with at least one of the plurality of electrodes (1, 5; 10, 14, 18), said providing of the layered device structure comprising steps of - providing an organic semiconducting layer (3; 12, 16), - applying a structuring layer to the organic semiconducting layer (3; 12, 16), the structuring layer having a first region and a second region, the first region being covered by a layer material, - applying a contact improving layer (4; 13) at least in the first region by depositing an organic dopant material, - removing the structuring layer at least in the second region, and - structuring the contact improving layer, - providing an organic semiconducting layer (3; 12, 16), - applying a structuring layer to the organic semiconducting layer (3; 12, 16), the structuring layer having a first region and a second region, the first region being covered by a layer material, - applying a contact improving layer (4; 13) at least in the first region by depositing an organic dopant material, - removing the structuring layer at least in the second region, and - structuring the contact improving layer,
A method of preventing marine biofouling of a substrate by a marine biofouling organism, comprising applying a protective coating to the substrate, said coating containing medetomidine (S,R)-4 -[1-(2, 3-dimethyl phenyl)-ethyl]-1H-imidazole)) bound by ionic binding to a polymer backbone selected from polystyrene-block-poly(ethylene-ran-butylene)-block-polystyrene (der-PS), said polymer backbone modified by being bound to a sulfonated substance for controlling the release of the biocide from the protective coating.
Pad for training of inserting a catheter or needle into a blood vein, the pad comprises at least one fluid connector and at least one fluid passageway or bore, the fluid connector is fluidly connected to the fluid passageway or bore, the fluid passageway or bore simulates a blood vein, the fluid passageway or bore can be inflated by pressurising with a fluid through the at least one connector, characterised in that the pad is shaped for releasable compression fitting into a pad frame that fits around the sides of the pad, the at least one fluid connector is on an underside of the pad, as male or female connectors, for making the connections with corresponding female or male connector parts when detachably inserting the pad into the pad frame, wherein connector parts on the underside also function as detachable fastening.
An apparatus, comprising: a feed wheel shaft; a feed wheel mounted on the feed wheel shaft; a feed wheel gear coupled with the feed wheel shaft; a thumper arm mounted on the feed wheel shaft; and a thumper assembly mounted on the thumper arm, the thumper assembly comprises: a thumper body with a first mounting surface for holding a thumper wheel gear and a thumper roller of a thumper wheel and a second mounting surface for holding an intermediate gear, and wherein the thumper wheel is timed with the feed wheel upon installation of the thumper assembly onto the thumper arm; and wherein the timing of the thumper wheel and feed wheel is maintained as long as the feed wheel gear, intermediate gear, and thumper wheel gear are meshed. a feed wheel shaft; a feed wheel mounted on the feed wheel shaft; a feed wheel gear coupled with the feed wheel shaft; a thumper arm mounted on the feed wheel shaft; and a thumper assembly mounted on the thumper arm, the thumper assembly comprises: a thumper body with a first mounting surface for holding a thumper wheel gear and a thumper roller of a thumper wheel and a second mounting surface for holding an intermediate gear, and wherein the thumper wheel is timed with the feed wheel upon installation of the thumper assembly onto the thumper arm; and wherein the timing of the thumper wheel and feed wheel is maintained as long as the feed wheel gear, intermediate gear, and thumper wheel gear are meshed.
A method of designing a sports article, comprising: (a) scanning at least one body part of at least a first person; (b) creating a first digital model of the body part of the first person; (c) creating a digital model of the sports article; (d) digitally arranging the digital model of the sports article on the first digital model of the body part, while allowing the digital model of the sports article to stretch digitally; and (e) digitally modifying at least one property of the digital model of the sports article based on the first digital model of the body part and the digital model of the sports article, calculating at least one force on the basis of the first digital model of the body part or the average digital model of the body part and the digital model of the sports article, and wherein digitally modifying the property of the digital model of the sports article is at least partially based on the calculated force, wherein digitally modifying the at least one property of the digital model of the sports article comprises digitally modifying a thickness of the sports article. (a) scanning at least one body part of at least a first person; (b) creating a first digital model of the body part of the first person; (c) creating a digital model of the sports article; (d) digitally arranging the digital model of the sports article on the first digital model of the body part, while allowing the digital model of the sports article to stretch digitally; and (e) digitally modifying at least one property of the digital model of the sports article based on the first digital model of the body part and the digital model of the sports article, calculating at least one force on the basis of the first digital model of the body part or the average digital model of the body part and the digital model of the sports article, and wherein digitally modifying the property of the digital model of the sports article is at least partially based on the calculated force, wherein digitally modifying the at least one property of the digital model of the sports article comprises digitally modifying a thickness of the sports article. calculating at least one force on the basis of the first digital model of the body part or the average digital model of the body part and the digital model of the sports article, and wherein digitally modifying the property of the digital model of the sports article is at least partially based on the calculated force, wherein digitally modifying the at least one property of the digital model of the sports article comprises digitally modifying a thickness of the sports article.
A method for producing a biodegradable polyurea/polyurethane microcapsule, which comprises the following steps in this order: (a) carrying out a first polymerisation and/or crosslinking step comprising: providing an internal non-aqueous phase comprising at least one polyisocyanate having two or more isocyanate groups and at least one lipophilic active ingredient to be encapsulated; providing an external aqueous phase comprising at least one protective colloid and optionally an emulsifier; mixing the internal non-aqueous phase and the external aqueous phase to obtain an oil-in-water emulsion; adding at least a first amino acid or an amino acid hydrochloride and a catalyst; (b) carrying out a second polymerisation and/or crosslinking step by adding at least one hydroxyl group donor; (c) carrying out a third polymerisation and/or crosslinking step by adding at least one second amino acid, in particular at a temperature of at least 60°C, to obtain a microcapsule dispersion; (d) curing of the microcapsule dispersion at a temperature of at least 60 °C for a period of at least 60 minutes; (e) adding at least one release agent and incorporation of the release agent into the microcapsule shell; (f) post-curing the polyurea microcapsule obtained in step (e); and optional: (g) separating the microcapsule from the microcapsule dispersion and, if necessary, drying the microcapsule. (a) carrying out a first polymerisation and/or crosslinking step comprising: providing an internal non-aqueous phase comprising at least one polyisocyanate having two or more isocyanate groups and at least one lipophilic active ingredient to be encapsulated; providing an external aqueous phase comprising at least one protective colloid and optionally an emulsifier; mixing the internal non-aqueous phase and the external aqueous phase to obtain an oil-in-water emulsion; adding at least a first amino acid or an amino acid hydrochloride and a catalyst; providing an internal non-aqueous phase comprising at least one polyisocyanate having two or more isocyanate groups and at least one lipophilic active ingredient to be encapsulated; providing an external aqueous phase comprising at least one protective colloid and optionally an emulsifier; mixing the internal non-aqueous phase and the external aqueous phase to obtain an oil-in-water emulsion; adding at least a first amino acid or an amino acid hydrochloride and a catalyst; (b) carrying out a second polymerisation and/or crosslinking step by adding at least one hydroxyl group donor; (c) carrying out a third polymerisation and/or crosslinking step by adding at least one second amino acid, in particular at a temperature of at least 60°C, to obtain a microcapsule dispersion; (d) curing of the microcapsule dispersion at a temperature of at least 60 °C for a period of at least 60 minutes; (e) adding at least one release agent and incorporation of the release agent into the microcapsule shell; (f) post-curing the polyurea microcapsule obtained in step (e);
An oral care composition comprising, by total weight of the composition: (a) 15 to 35 weight % calcium carbonate; and (b) from 10 to 20 weight % talc; wherein the total concentration of talc and calcium carbonate in the composition is from greater than 35 weight % to 42 weight %, by total weight of the composition; and wherein the calcium carbonate comprises natural calcium carbonate or precipitated calcium carbonate. (a) 15 to 35 weight % calcium carbonate; and (b) from 10 to 20 weight % talc;
An immunogenic composition comprising a. an attenuated Mycoplasma bovis bacterium strain deposited with the ATCC under accession numbers PTA-8694, PTA-8695, or PTA-8696, and combinations thereof; and b. one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of microbiological infection in cattle caused by a cattle pathogen other than Mycoplasma bovis. a. an attenuated Mycoplasma bovis bacterium strain deposited with the ATCC under accession numbers PTA-8694, PTA-8695, or PTA-8696, and combinations thereof; and b. one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of microbiological infection in cattle caused by a cattle pathogen other than Mycoplasma bovis.
Tyre for motorcycles, having a tread band comprising a central annular portion symmetrically located astride an equatorial plane (X-X) and two shoulder annular portions located on axially opposite sides with respect to the central annular portion; the tread band having a void-to-rubber ratio not greater than 25%; the central annular portion having an axial extension not greater than 65% of the axial development of the tread band and said central portion having at least one module circumferentially repeated; each shoulder portion having an axial extension not greater than 40% of the axial development of the tread band; said module comprising at least one pair of first grooves with substantially circumferential course, at least partially located on opposite sides with respect to the equatorial plane (X-X), wherein the central annular portion has a void-to-rubber ratio not smaller than 10% and said module comprises a plurality of second grooves located substantially transversally with respect to the equatorial plane (X-X), said tyre being characterized in that in a same module at least one second groove is located completely between two first grooves so as to cross the equatorial plane (X-X); said substantially transverse second grooves defining in each module together with said substantially circumferential first grooves at least two tread band solid portions, said second grooves having at least one end spaced away from an adjacent first groove by a distance (s) so as to form a substantially continuous tread portion adapted to connect at least two tread band solid portions.
A method of Timing Advance, TA, handling for sidelink,SL,-assisted positioning of a first User Equipment, UE, the method comprising: determining the first UE is configured to transmit an SL Positioning Reference Signal, SL-PRS, to a second UE to perform the SL-assisted positioning; determining a length of time for a guard period based on a configuration of the first UE for transmitting the SL-PRS, wherein the guard period comprises a period of time during which the SL-PRS is transmitted by the first UE; and sending, to a serving Transmission Reception Point, TRP, of the first UE, a message indicating the guard period and comprising a TA-related request, wherein the TA-related request includes: a request to postpone applying a TA command received by the first UE until after the guard period, or a request for the serving TRP not to send a TA command to the first UE during the guard period. determining the first UE is configured to transmit an SL Positioning Reference Signal, SL-PRS, to a second UE to perform the SL-assisted positioning; determining a length of time for a guard period based on a configuration of the first UE for transmitting the SL-PRS, wherein the guard period comprises a period of time during which the SL-PRS is transmitted by the first UE; and sending, to a serving Transmission Reception Point, TRP, of the first UE, a message indicating the guard period and comprising a TA-related request, wherein the TA-related request includes: a request to postpone applying a TA command received by the first UE until after the guard period, or a request for the serving TRP not to send a TA command to the first UE during the guard period. a request to postpone applying a TA command received by the first UE until after the guard period, or a request for the serving TRP not to send a TA command to the first UE during the guard period.
Flexible spring element made of a fibre-reinforced plastics composite material (4, 23), wherein the flexible spring element comprises two functional layers (2, 3), in each case one made of a fibre-reinforced plastics composite material on two mutually opposite sides (9, 10) of a central plane, wherein flexible spring fibres in the functional layers (2, 3) are oriented parallel to one another at least in bundles and extend in a longitudinal direction of the flexible spring element, wherein the flexible spring element comprises at least one curved portion, in which the central plane of the flexible spring element extending between the two functional layers (2, 3) extends curved by more than 90° in the longitudinal direction of the flexible spring element when unloaded, wherein the flexible spring element comprises at least one longitudinal portion in which the central plane of the flexible spring element has either no significant curvature or a curvature reversal when unloaded, and wherein when the flexible spring element is deflected as intended, a functional layer portion arranged in the curved portion and directed outwards is subjected to tensile stress and a functional layer portion arranged oppositely in the curved portion and directed inwards is subjected to compressive stress, characterised in that the flexible spring element comprises, in the at least one longitudinal portion, at least one matrix material discharge layer that extends parallel to the two functional layers (2, 3) and in the longitudinal direction and that comprises at least a fraction of discharge layer fibres oriented differently from the longitudinal direction of the flexible spring element, and in that, within the at least one curved portion, a first volume fraction of flexible spring fibres in the functional layers (2, 3) is smaller, preferably several % smaller, than a second volume fraction of flexible spring fibres in the functional layers (2, 3) within the at least one longitudinal portion.
A compound of formula: and pharmaceutically acceptable salts thereof, wherein X 1 is selected from the group consisting of -CH 2 -, or -O-; R is a C 6-10 aryl or C 5-10 heterocyclyl group, said aryl or heterocyclyl group optionally substituted with 1 to 3 groups of R a; R a represents: (a) halogen, (b) hydroxy, (c) -O-C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (d) -C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (e) cyano, (f) -NR A R B, (g) t-butoxycarbonyl, -C(=O)-R C, -S n -R C, C 5-10 heterocyclyl, and C 6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of R C; RA and RB are selected from the group consisting of (i) hydrogen, (ii) -C 1-6 alkyl, or RA and RB are linked together with the nitrogen to which they are both attached to form a 2-6 membered carbocyclic ring, wherein one or two of the ring carbon atoms is replaced by a nitrogen, oxygen or sulfur, and the carbocyclic is optionally substituted with one or more C 1-6 alkyl, RC is selected from the group consisting of (i) hydrogen, (ii)-C 1-6 alkyl, (iii)-O-C 1-6 alkyl, (iv) CF3, (v) halogen, (vi) cyano, and n is 0, 1 or 2. X 1 is selected from the group consisting of -CH 2 -, or -O-; -CH 2 -, or -O-; R is a C 6-10 aryl or C 5-10 heterocyclyl group, said aryl or heterocyclyl group optionally substituted with 1 to 3 groups of R a; R a represents: (a) halogen, (b) hydroxy, (c) -O-C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (d) -C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (e) cyano, (f) -NR A R B, (g) t-butoxycarbonyl, -C(=O)-R C, -S n -R C, C 5-10 heterocyclyl, and C 6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of R C; (a) halogen, (b) hydroxy, (c) -O-C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (d) -C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of halo; (e) cyano, (f) -NR A R B, (g) t-butoxycarbonyl, -C(=O)-R C, -S n -R C, C 5-10 heterocyclyl, and C 6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of R C; RA and RB are selected from the group consisting of (i) hydrogen, (ii) -C 1-6 alkyl, (i) hydrogen, (ii) -C 1-6 alkyl, or RA and RB are linked together with the nitrogen to which they are both attached to form a 2-6 membered carbocyclic ring, wherein one or two of the ring carbon atoms is replaced by a nitrogen, oxygen or sulfur, and the carbocyclic is optionally substituted with one or more C 1-6 alkyl, RC is selected from the group consisting of (i) hydrogen, (ii)-C 1-6 alkyl, (iii)-O-C 1-6 alkyl, (iv) CF3, (v) halogen, (vi) cyano, and (i) hydrogen, (ii)-C 1-6 alkyl, (iii)-O-C 1-6 alkyl, (iv) CF3, (v) halogen, (vi) cyano, and n is 0, 1 or 2.
Iron complex compounds comprising at least one ligand of the formula: wherein the arrows individually represent a coordinate bond to one or different iron atoms, R 1 is selected from the group consisting of optionally substituted alkyl, and optionally substituted alkoxycarbonyl, R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, halogen and cyano, or R 1 and R 2, together with the carbon atoms to which they are bonded, form an optionally substituted 5- or 6-membered ring, which may optionally contain one or more heteroatoms, R 3 and R 4 are the same or different and are individually selected from the group consisting of hydrogen, optionally substituted amino, and optionally substituted alkyl, or R 3 and R 4, together with the nitrogen atom to which they are bonded, form an optionally substituted 3- to 6-membered ring, which may optionally contain one or more further heteroatoms, or R 2 and R 3 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring while forming a ligand of the formula (Ia): wherein R 1 and R 4 are defined as above, or R 2 and R 3 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring, and R 1 and R 2 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring, while forming a ligand of the formula (Ib): wherein R 4 is defined as above, or pharmaceutically acceptable salts thereof, for use in the treatment and prophylaxis of iron deficiency diseases and iron deficiency anemias and the symptoms associated therewith. the arrows individually represent a coordinate bond to one or different iron atoms, R 1 is selected from the group consisting of optionally substituted alkyl, and optionally substituted alkoxycarbonyl, R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, halogen and cyano, or R 1 and R 2, together with the carbon atoms to which they are bonded, form an optionally substituted 5- or 6-membered ring, which may optionally contain one or more heteroatoms, R 3 and R 4 are the same or different and are individually selected from the group consisting of hydrogen, optionally substituted amino, and optionally substituted alkyl, or R 3 and R 4, together with the nitrogen atom to which they are bonded, form an optionally substituted 3- to 6-membered ring, which may optionally contain one or more further heteroatoms, or R 2 and R 3 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring while forming a ligand of the formula (Ia): wherein R 1 and R 4 are defined as above, or R 2 and R 3 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring, and R 1 and R 2 together form a saturated or unsaturated, optionally substituted 5- or 6-membered ring, while forming a ligand of the formula (Ib): wherein R 4 is defined as above, or pharmaceutically acceptable salts thereof, for use in the treatment and prophylaxis of iron deficiency diseases and iron deficiency anemias and the symptoms associated therewith.